Study to leverage deep learning-enabled analysis of the
aggregation of real-world multimodal data to validate predictive
signatures associated with response to immunotherapy and prognosis
of patients with stage IV non-small cell lung cancer
Large-scale, multicentric real-world study aims to enroll
4,000 patients from approximately 30 sites across North America, Europe, and Latin
America
BOSTON and LAUSANNE, Switzerland, Dec. 1, 2021 /PRNewswire/ -- SOPHiA GENETICS
SA (Nasdaq: SOPH), the creator of a global data pooling and
knowledge sharing platform that advances data-driven medicine,
announced today the launch of their DEEP-Lung-IV clinical study
(NCT04994795). The study leverages deep learning-enabled analysis
of the aggregation of multimodal clinical, biological, genomic and
radiomics data to identify and validate predictive signatures
associated with response to immunotherapy and prognosis of patients
with metastatic non-small cell lung cancer (NSCLC).
![SOPHiA GENETICS Logo SOPHiA GENETICS Logo](https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg)
Over the last decade, immunotherapy has revolutionized the
treatment landscape for patients diagnosed with stage IV NSCLC and
has become the standard of care in the frontline setting for
patients without oncogene-activating mutations. Despite the
clinical promise of immunotherapy, significant challenges remain as
the majority of NSCLC patients fail to respond to immune checkpoint
inhibitors. Today, PD-L1 is the only standard predictive biomarker
for immune checkpoint inhibitor efficacy. However, it remains
a very suboptimal biomarker with several well-characterized issues
limiting its clinical utility. Thus, an urgent need exists to
discover new predictive biomarkers of response to
immunotherapy.
SOPHiA GENETICS' DEEP-Lung-IV clinical study aims to predict
immunotherapy treatment response at first evaluation at the
individual patient level using data across multiple modalities
including genomics, radiomics, clinical and biological data. The
study also aims to validate an algorithm that will allow the
prediction of outcomes at the individual patient such as
progression-free survival (PFS) and overall survival (OS). This
predictive model will help identify patients that are likely to
benefit from immunotherapy versus those that are not, as well as
stratify patients according to risk, helping clinicians make more
informed therapeutic decisions for their patients and supporting
biopharma to ensure the right patients are selected for clinical
trials.
"We are very excited about the opportunity to validate
multimodal predictive models through such an innovative
large-scale, multicentric, real-world clinical study. We aim to
generate entirely novel actionable insights to improve clinical
outcomes for patients with stage IV NSCLC treated with
immunotherapy and develop next-generation patient stratification
strategies to support the selection of the right patients for
clinical trials" said Dr. Philippe Menu, Chief Medical Officer at
SOPHiA GENETICS. "The analytical power of the multimodal SOPHiA
GENETICS platform applied to this important clinical question
illustrates the potential benefit for patients in embracing a
future of Data-Driven Medicine."
To learn more about the DEEP-Lung-IV clinical study, please
visit https://clinicaltrials.gov/ct2/show/NCT04994795.
About SOPHiA GENETICS:
SOPHiA GENETICS is a healthcare
technology company dedicated to establishing the practice of
data-driven medicine as the standard of care and for life sciences
research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-based SaaS platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by more than 780 hospital,
laboratory, and biopharma institutions globally.
More info: SOPHiAGENETICS.COM;
follow @SOPHiAGENETICS on Twitter.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg